Eric Lefkofsky’s latest start-up venture, a genomics firm called Tempus, is helping doctors at the Mayo Clinic make breakthroughs in treating cancer patients. And they aren’t stopping there. Tempus has several other medical partnerships in the works and is hoping to secure others, all with the intention of finding the best treatments for cancer sufferers.
Tempus is gathering the genomic information of over 1000 patients in the Mayo Clinic Partnership alone. This information will then be parsed, cataloged, analyzed, and compared to others to see where similarities and differences lie. In addition, the data will be updated throughout the patient’s treatment and paired with which treatments are successful for which patients. Eric Lefkofsky’s company will then look for patterns that can help the doctors.
What They’re Looking For
Lefkofsky’s goal in all of this is to find a common link between people for whom certain therapies seem to work. Currently, the field of cancer treatment is a bit like playing darts blindfolded. Physicians are forced, on some level, to throw treatments at patients, hoping to find the right one for them. Tempus hopes to find a genetic link — to develop the ability to point to a specific set of DNA and let the patient know which therapies will work best for unique situation.
How It Will Help
The key to treating cancer is to find an effective therapy quickly and safely. Doctors must be aggressive enough to stop the development of cancer right away while subjecting the patient’s body to as little damage as possible from invasive treatments. If Lefkofsky’s plan is successful, the doctors will know immediately which therapies the individual patient will respond to, saving precious time, money, and lives.
For more information on Eric Lefkofsky’s brilliant new start-up Tempus, see this article in the Chicago Tribune.
Learn More: lefkofskyfoundation.com/
Aches and pain are a part of everyone’s life to some degree. Muscle and joint pain can basically cripple you if the problem isn’t addressed accordingly. To alleviate the pain, radical treatments and surgery has been used for centuries. Unfortunately, most people aren’t willing to go under the knife to achieve a pain-free lifestyle. On the other hand, there are a wide variety of pharmaceutical painkillers on the market, but you must have a prescription to obtain them. These pills will definitely decrease the pain in your body, but many of these medications are a bit too powerful for regular use.
When it comes to pain relief, masking the pain isn’t the best route to take. Pain is a surefire way of telling you that something is wrong. If you mask the pain, then you could possibly reinjure yourself. This is the perfect give and take situation, and it’s the perfect catch-22. Heal N Sooth goes about eliminating pain the natural-route way. Systemic-Enzyme Therapy releases beneficial enzymes into the bloodstream, which is one of the main lines of defense. Heal N Sooth can handle the toughest of pain and discomfort. This includes:
• Back Pain
• And more
On the other hand, when inflammation is being reduced to a minimum, it’s great for cancer-prevention as well as great for memory-loss prevention. Studies have shown that just 400 mg of Bromelain per day is great for decreasing swelling and pain. Of course, this advantageous ingredient is offered with this formula. All in all, Heal N Soothe’s benefits can go on for days, but who knows how much better it will get in the near future.
To know more visit @: vimeo.com/healnsoothe
Clay Siegall is a by profession a doctor. He co-founded Seattle Genetics in the year 1998. Clay heads the company as the current president, Chief Executive Officer and Chairman of the Board of Directors. Seattle Genetics is a biotechnology company with a primary goal of building a diverse pipeline of antibody-based cancer therapies, including brentuximab vedotin. In 2011, the cancer-based treatment was approved by the U.S. Food and Drug Administration. Dr Clay is recognized globally in medicine industry for his broad expertise and diverse experience.
Seattle Genetics, region’s dominant biotech firm is currently diverting its focus on a drug as an antibody-drug conjugate. The drugs target protein molecules that cause an immune system to produce antibodies. In a simplistic form, the drug generates cells that kill cancer cells while not harming healthy human body tissue. The intelligent approach has practically reduced the damage caused cancer traditional chemotherapy and radiation methods.
In addition to Seattle genetics series of drug production, the second drug is known as the number 33A. 33A targets acute myeloid leukemia condition, which has been a dire diagnosis for uncountable years. Additionally, the company has also a third edition drug known as the 22ME. The third drug primary goal is to generate cells that kill bladder cancer and other urothelial cancers cells. Lastly, the fourth drug is LIV1. It targets breast cancer.
Under his leadership, Dr. Siegall has also guided Seattle Genetics to capital-raising activities through public and private events. The biotech company has secured more than six hundred million dollars including the corporation’s first public offering recorded in the year 2001.
In addition to clay expertise, he is also a prolific author. The man has published more than seventy publications, and he also holds around fifteen patents. In addition to Seattle Genetics, Dr. Clay Siegall serves as a director of Alder Biopharmaceuticals, together with the Mirna Therapeutics Corporation. The companies as mentioned earlier are both privately-held biotechnology companies.
Dr. Siegall attended the University of Maryland where he acquired a bachelor’s degree in zoology. He later upgraded his education by attaining a master’s degree in and Genetics from the George Washington University. He began his profession at the National Cancer Institute from the year 1988 to 1991. He later resigned from his position and moved to the Bristol-Myers Squibb Pharmaceutical Research Institute where he worked for an approximate of six years. Then in 1998, clay Siegall co-founded Seattle genetics.